Company Profile

Zymogenetics Inc
Profile last edited on: 12/2/2023      CAGE: 54SK9      UEI: UL1TMXJPLQJ5

Business Identifier: Recombinant thrombin. Protein-based therapeutics for the prevention or treatment of human diseases
Year Founded
First Award
Latest Award
Program Status
Inactive (Acquired)
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

1201 Eastlake Avenue East
Seattle, WA 98102
   (206) 442-6600
Location: Single
Congr. District: 07
County: King

Public Profile

Formerly operating as an independent company after 12 years as a wholly owned subsidiary of Novo Nordisk A/S, in September 2010, ZymoGenetics Inc was acquired by Bristol-Myers Squibb. ZymoGenetics Inc. is focused on the discovery, development and commercialization of therapeutic proteins for the treatment of human disease. The Company has been longtime active in the area of therapeutic proteins having contributed to the discovery or development of many marketed recombinant protein products. These products include recombinant versions of proteins previously made from human or animal sources (Novolin (insulin) and GlucaGen (glucagon), marketed by Novo Nordisk) and novel proteins that come from its discoveries (NovoSeven (Factor VIIa), marketed by Novo Nordisk, as well as Regranex (platelet-derived growth factor), marketed by Ortho-McNeil Pharmaceuticals, Inc., a Johnson & Johnson company, and Cleactor (tPA analog), marketed by Eisai Co., Ltd).

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
1988 2 NIH $600,000
Project Title: Cloning & expressing human colony stimulation factor
1988 2 NIH $550,000
Project Title: Expression of human protien C in mammalian cells
1987 1 NIH $50,000
Project Title: Cloning/sequencing/expression of human bsa lipase cdna
1987 1 NIH $50,000
Project Title: Cloning and expression of human interleukin-3
1986 1 NIH $50,000
Project Title: Cloning & expression of human antibody for anthrax exotoxin

Key People / Management

  Bruce L A Carter -- President and Chief Executive Officer

  Douglas Edward Williams -- President

  John Forstrom

  Frederick Hagen

  Wayne R Kindsvogel

  Claus Kuhl

  Mark J Murray